Alison Crawford
Director, Immuno‑Oncology Regeneron Pharmaceuticals
Seminars
Wednesday 24th June 2026
Advancing Immuno‑Oncology Breakthroughs & Reducing Toxicity Risks Through Next‑Generation Preclinical Models
11:30 am
- Gaining insights using cutting‑edge preclinical models to model toxicity mitigation strategies and on‑target/off‑tumor effects
- Understanding optimized dosing strategies can expand therapeutic windows and improve the safety profile of next‑generation immunotherapies
